The proprotein convertase subtilisin/kexin type 9 inhibitors or monoclonal antibodies likely represent the greatest advance in lipid management in 30 years. In 2015 the US Food and Drug Administration approved both alirocumab and evolocumab for high-risk patients with familial hypercholesterolemia (FH) and clinical atherosclerotic cardiovascular disease requiring additional lowering of low-density lipoprotein cholesterol. Though many lipid specialists, cardiovascular disease prevention experts, endocrinologists, and others prescribed the drugs on label, they found their directives denied 80% to 90% of the time. The high frequency of denials prompted the American Society for Preventive Cardiology (ASPC), to gather multiple stakeholder organizations including the American College of Cardiology, National Lipid Association, American Association of Clinical Endocrinologists (AACE), and FH Foundation for 2 town hall meetings to identify access issues and implement viable solutions. This article reviews findings recognized and solutions suggested by experts during these discussions. The article is a product of the ASPC, along with each author writing as an individual and endorsed by the AACE.
Pharmacology, Toxicology and Pharmaceutical Science
6
8%
Agricultural and Biological Sciences
4
5%
Psychology
4
5%
Biochemistry, Genetics and Molecular Biology
3
4%
Other
9
12%
Unknown
32
43%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 183. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2026.
All research outputs
#278,495
of 34,795,682 outputs
Outputs from Clinical Cardiology: International Journal for Cardiovascular Diseases
#20
of 2,551 outputs
Outputs of similar age
#4,643
of 353,853 outputs
Outputs of similar age from Clinical Cardiology: International Journal for Cardiovascular Diseases
#3
of 36 outputs
Altmetric has tracked 34,795,682 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,551 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,853 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.
